Night Blindness Treatment Market Report 2026

The night blindness treatment market size has grown strongly in recent years. It will grow from $4.2 billion in 2025 to $4.46 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high prevalence of malnutrition, limited access to eye care services, growing awareness of vision disorders, increasing geriatric population, advancements in ophthalmic diagnostics.

The night blindness treatment market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising investment in eye health programs, increasing demand for personalized treatments, expansion of gene therapy applications, growth in healthcare infrastructure, improving reimbursement policies. Major trends in the forecast period include rising prevalence of vitamin A deficiency, increasing adoption of early diagnosis techniques, growth in minimally invasive eye surgeries, expanding use of nutritional and preventive therapies, improved access to vision care in emerging economies.

The rising prevalence of cataracts is expected to drive the growth of the night blindness treatment market in the coming years. Cataracts are characterized by clouding of the eye’s lens, which impairs vision. Factors such as increased exposure to ultraviolet (UV) light, smoking, and poor diet contribute to cataract development. Cataracts reduce the eye’s ability to distinguish between light and dark shades, which is essential for effective night vision. This diminished contrast sensitivity makes it difficult to navigate and recognize objects in low-light conditions. For instance, in May 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, hospital admissions for cataract surgery in England rose to over 516,000 in the financial year ending 2023, equivalent to 4,679 per 100,000 people, marking a notable increase from the previous year’s rate of 3,803 per 100,000. Therefore, the increasing prevalence of cataracts is contributing to the expansion of the night blindness treatment market.

Major companies operating in the night blindness treatment market are focusing on developing innovative genetic therapies to address the underlying mutations responsible for the condition, enhancing treatment efficacy and improving patient outcomes. Genetic therapies treat night blindness by targeting and repairing specific gene defects that affect retinal function, with the potential to restore vision in individuals with inherited retinal disorders such as retinitis pigmentosa. For example, in August 2023, HuidaGene Therapeutics, a U.S.-based clinical-stage biotechnology company, introduced HG004, a gene therapy aimed at treating inherited retinal diseases, including Leber’s congenital amaurosis. Preclinical studies have demonstrated its potential to restore retinal function and alleviate night blindness and other vision impairments associated with RPE65 gene mutations.

In October 2025, AviadoBio Ltd., a UK-based developer of targeted gene therapies for neurodegenerative and ocular conditions, entered into an exclusive option-license agreement with UgeneX Therapeutics to advance and potentially commercialize UGX-202, an optogenetics-based gene therapy designed to restore vision in patients with retinitis pigmentosa and other inherited retinal diseases. Through this collaboration, AviadoBio aims to expand its next-generation ocular gene therapy portfolio by leveraging UgeneX’s optimized AAV-based optogenetic platform to address severe photoreceptor loss and associated night blindness. UgeneX Therapeutics is a China-based biotechnology company specializing in ophthalmic gene therapy innovations, supported by a proprietary platform and a growing pipeline of retinal gene therapy candidates.

Major companies operating in the night blindness treatment market are Johnson & Johnson Private Limited, Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc, Bausch Health Companies Inc, Cipla Inc, Nature’s Way, Garden of Life, Apellis Pharmaceuticals Inc, Solgar, Acucela Inc, Swanson Health Products, Astellas Pharma Inc, F. Hoffmann‑La Roche Ltd, Applied Genetic Technologies Corp, MeiraGTx Holdings plc, GenSight Biologics, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Opthea Limited, Oxurion NV, EyePoint Pharmaceuticals Inc, Ocuphire Pharma Inc.

North America was the largest region in the night blindness treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the night blindness treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the night blindness treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the night blindness treatment market by increasing the cost of imported pharmaceuticals, diagnostic equipment, and surgical devices used in ophthalmic care. These trade barriers have particularly affected medication and surgical treatment segments, with Asia-Pacific and Latin America facing higher price sensitivity due to reliance on imported vitamin supplements and medical devices. Delays in supply chains have also impacted hospitals and clinics dependent on advanced diagnostic tools. However, tariffs have encouraged local manufacturing of supplements and basic ophthalmic equipment, supporting domestic production and reducing long-term dependency on imports.

The night blindness treatment market research report is one of a series of new reports that provides night blindness treatment market statistics, including night blindness treatment industry global market size, regional shares, competitors with a night blindness treatment market share, detailed night blindness treatment market segments, market trends and opportunities, and any further data you may need to thrive in the night blindness treatment industry. This night blindness treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Night blindness treatment refers to medical interventions designed to address conditions such as vitamin A deficiency and other factors that impair vision in low-light environments. The goal is to improve visual acuity in dim conditions and enhance overall visual function by targeting the underlying causes. This treatment focuses on alleviating symptoms and enabling patients to see more effectively in low-light and nighttime settings.

The primary treatments in the night blindness market include medication, surgery, and other therapeutic approaches. Night blindness medications are aimed at improving vision in low-light conditions, often by treating underlying issues such as vitamin A deficiency, retinitis pigmentosa, or other retinal disorders. Diagnosis of night blindness can involve blood tests, color vision assessment, pupil light reflex evaluation, refraction, retinal examination, electroretinogram (ERG), and other methods. Symptoms may include eye pain, vomiting, cloudy vision, halos, light sensitivity, difficulties with distance vision, headaches, and more. The end users of these treatments include clinics, hospitals, and other healthcare settings.

The night blindness treatment market consists of revenues earned by entities by providing services such as diagnostic services, medical management and consultation, surgical interventions, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The night blindness treatment market also includes sales of night vision goggles, retinal implants and prosthetics, electroretinography (ERG) systems, vitamin A supplements, and intraocular injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.